Hong Kong Rongxin Biotech Co.,Ltd
Hong Kong RongXin Bio-Tech Co.,Ltd is a Chinese biopharmaceutical entity established in 2009. Located in Xi’an, the company has positioned itself in the development and production of steroid hormone APIs and their intermediates, alongside growth hormone and peptide hormone products. The information available emphasizes a focus on custom processing and cultivation of capabilities related to steroid hormone chemistry, as well as the wholesale and sales of APIs and intermediates. The firm’s stated activities include the development and production of APIs and intermediates for steroid hormones, which suggests an emphasis on scalable manufacturing and customization to meet partner specifications. The profile indicates a commitment to evolving product lines and process capabilities in response to market demands within the biotechnology and pharmaceutical sectors.
The company description also references the development and production of growth hormones and peptide hormones, highlighting a broader capability in peptide-related bioproducts. While the available data does not provide specifics on regulatory certifications, production facilities, or distribution networks, the combination of API/intermediate production with peptide hormone development implies a vertically integrated approach that may encompass research, development, and small- to mid-scale manufacturing activities.
Information available from the original profile does not include operational details such as geographic reach, partner networks, or quality assurance systems. Website content notes that product details are under update and directs inquiries via email, suggesting ongoing updates to product catalogs or services. Given the limited accessible information, the profile presents a factual overview of the company’s stated expertise without assumptions about capabilities beyond what is explicitly described.
In summary, Hong Kong RongXin Bio-Tech Co.,Ltd appears to be a Xi’an-based biopharmaceutical firm with established activities in steroid hormone APIs and intermediates, and a parallel emphasis on growth hormone and peptide hormone development and production. The available data points to a company that combines pharmaceutical ingredients development with potential manufacturing and wholesale activities, operating within the biotech and chemical sectors of China.
